http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-093795-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9008466a40998f8be8e54cd3aceb10a2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 |
| filingDate | 2013-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feb4f9a4a122abf04e2490785aa8ecca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e696c056e82eb550b229c61f24cfd03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de9a6a98f629b284f7d68ab9eb9fb62b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df747d4b4b8962d61d978b0db05a665b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae102ac85ba305ff77fb2281b4c7c88e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16c4629e95fdcc82efee28ac246f2fe2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_592f25804f2d12b9ec506a48da4da7f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be9160e3963e14d4ade9a5b090841a8 |
| publicationDate | 2015-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-093795-A1 |
| titleOfInvention | PIRIDINUM OXIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES |
| abstract | Compounds that can act as phosphodiesterase 4 (PDE4) enzyme inhibitors and as M3 muscarinic receptor antagonists, compositions that comprise them and their use in therapies. Claim 1: A compound characterized in that it is of formula (1) wherein W is selected from aryl and heteroaryl; R¹ is hydrogen or is selected from the group consisting of: halogen, C₁₋₄ alkyl, C alco alkoxy, C₁₋₄ haloalkyl, hydroxy, -SO₂NR⁶R⁷, -CN, -NR⁸SO₂R⁹, -NR⁶R⁷, -CONR⁶R⁷ and -NR⁸COR⁹ and where C₁₋₄ alkyl is optionally substituted with one or more groups selected from C₃₋₇ cycloalkyl, hydroxy and -NR⁶R⁷ and where C₁₋₄ alkoxy is optionally substituted with one or more halogens or C₃₋₇ cycloalkyl groups where, R⁶ is hydrogen or C₁₋₆ alkyl; R⁷ is hydrogen or C₁₋₆ alkyl; R⁸ is hydrogen or C₁₋₆ alkyl; R⁹ is hydrogen or C₁₋₆ alkyl; n is an integer in the range between 1 and 3; R² is hydrogen or is selected from the group consisting of: halogen, C₁₋₄ alkyl, C alco alkoxy, C₁₋₄ haloalkyl, hydroxy, -SO₂NR¹⁰R¹¹, -CN and -NR¹²SO₂R¹³ and where C₁₋₄ alkyl and C₁₋ alkoxy ₄ are optionally substituted with a C₃₋₇ cycloalkyl group, R¹⁰ is hydrogen or C₁₋₆ alkyl; R¹¹ is hydrogen or C₁₋₆ alkyl; R¹² is hydrogen or C₁₋₆ alkyl; R¹³ is hydrogen or C₁₋₆ alkyl; m is an integer in the range between 1 and 3; p is zero or 1; L¹ is a group (CH₂) ₜ where t is 0 or an integer in the range between 1 and 3; L² is a group selected from (CH₂) q where q is an integer in the range between 1 and 3, ortho-, meta-, para-benzyl, ortho-, meta- and para-methylene oxybenzyl where the carbon atom of the chain of the benzyl group is attached to the nitrogen atom; R³ and R⁴ are different or equal and are independently selected from the group consisting of: H; C₃₋₇carbonyl cycloalkyl; C₁₋₆ alkyl, optionally substituted with one or more substituents selected from C₃₋₇ cycloalkyl or C₅₋₇ cycloalkenyl; C₁₋₆ haloalkyl; C₃₋₇ cycloalkyl; C₅₋₇ cycloalkenyl; C₂₋₆ alkenyl; and C₂₋₆ alkynyl; or R³ and R⁴, together with the atoms that interconnect them, form a 2,2-difluoro-1,3-dioxolane ring of formula (2) fused to the phenyl unit that joins the -OR³ and -OR⁴ groups, where asterisks indicate carbon atoms shared with said phenyl ring; R⁵ is selected from the group consisting of: CN, NO₂, CF₃ and halogen atoms; k is an integer in the range between 1 and 3; and A is a nitrogen-containing group that can be: a group (a) that is - (CH₂) ₛ-NR¹⁴R¹⁵ where s is an integer in the range between 1 and 4 and R¹⁴ and R¹⁵ are independently hydrogen or C₁ alkyl ₋₄; or a group (b) which is a monocyclic, bicyclic or tricyclic saturated heterocyclic ring system optionally substituted with one or two R¹⁶ groups which are in each case independently C₁₋₄ alkyl or benzyl; N-oxides in the pyridine ring, deuterated derivatives, and pharmaceutically acceptable salts and solvates thereof. |
| priorityDate | 2012-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.